# Evaluating the Efficacy of Retatrutide in Type 2 Diabetes with Obesity

Canonical source: https://retacompare.com/research/evaluating-the-efficacy-of-retatrutide-in-type-2-diabetes-with-obesity

Clinical Trials · 2026-04-13


    This study investigates the efficacy and safety of retatrutide in individuals with type 2 diabetes who also have obesity or overweight. The trial is designed to include a specific subset of participants with obstructive sleep apnea, highlighting the multifaceted approach to managing diabetes and related conditions. Over the course of approximately 89 weeks, participants will attend up to 24 visits to assess various health outcomes.

 What this source covers

The source details a clinical trial (NCT05929079) aimed at evaluating retatrutide (LY3437943) in participants diagnosed with type 2 diabetes mellitus and classified as obese or overweight. The study includes a subgroup of participants suffering from obstructive sleep apnea, indicating a comprehensive approach to understanding the drug's effects in a population with complex health issues. The trial is structured to last about 89 weeks and involves multiple visits for thorough monitoring.

 Why it matters for Retatrutide research

This study is significant as it contributes to the growing body of evidence surrounding retatrutide's role in managing type 2 diabetes, particularly in individuals who are also dealing with obesity or overweight. Understanding the efficacy and safety of retatrutide in this specific population can inform treatment protocols and potentially lead to improved patient outcomes. The inclusion of participants with obstructive sleep apnea further emphasizes the need for tailored approaches in diabetes management.

 Key findings or claims

The study evaluates the efficacy of retatrutide in participants with type 2 diabetes and obesity or overweight.

A subset of participants with obstructive sleep apnea is included in the trial.

The study duration is approximately 89 weeks, with up to 24 visits planned.

The trial aims to assess both the safety and efficacy of retatrutide.

Results may provide insights into managing diabetes in populations with additional health complications.

 Context and prior work

Retatrutide is part of a broader class of medications that target multiple pathways involved in glucose metabolism and appetite regulation, including GLP-1, GIP, and glucagon pathways. Prior research has shown that these pathways play a crucial role in weight management and glycemic control, making retatrutide a candidate for further exploration in diverse patient populations. The findings from this trial could align with existing literature that supports the efficacy of multi-hormonal approaches in treating obesity and diabetes.

 Practical takeaways for researchers

Researchers should consider the implications of retatrutide's efficacy in populations with comorbid conditions such as obesity and obstructive sleep apnea. The structured trial design, with multiple visits, allows for detailed monitoring of participant responses over time, which can yield valuable data for future studies. Additionally, the outcomes of this trial may inform clinical practices and guidelines for managing type 2 diabetes in patients with complex health profiles. For those interested in the broader context of peptide therapies, further reading on peptide stacking may provide additional insights.

 FAQ

 What is retatrutide?

Retatrutide is a novel medication being investigated for its efficacy in managing type 2 diabetes and obesity.

 How long will the study last?

The study is designed to last approximately 89 weeks, including multiple participant visits.

 Are there specific health conditions being considered in this trial?

Yes, the trial includes participants with type 2 diabetes who are also classified as obese or overweight, as well as a subset with obstructive sleep apnea.

 Source: ClinicalTrials.gov · NCT05929079 · published 2026-04-13.

## Sources

- ClinicalTrials.gov · NCT05929079: https://clinicaltrials.gov/study/NCT05929079